Compare Iron Mountain Inc (IRM) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Iron Mountain Inc vs Spyre Therapeutics Inc. Common Stock — how do they compare? Iron Mountain Inc trades at $111 (market cap $34.12B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Iron Mountain Inc is far larger — about 4.5× Spyre Therapeutics Inc. Common Stock's market cap, and Iron Mountain Inc pays a 3.02% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Iron Mountain Inc for 80 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| IRM | SYRE | |
|---|---|---|
Market Cap | $34.12B | $7.52B |
Volume | 1,143,756 | 1,441,031 |
Sector | Real Estate | Health |
52-Week High | $133.06 | $108.92 |
52-Week Low | $78.86 | $22.18 |
Typical Hold Time | 80 Days | 0 Days |
Enterprise Value | $53.53B | $6.52B |
Dividend Yield | 3.02% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Iron Mountain (IRM) trades at $110.86, down 3.68% on the day, amid a neutral technical signal. The company shows steady revenue growth, with 2025 revenue at $6.90B and a net income margin of 5.54%, though profitability has been volatile. Recent news highlights expansion in data centers and digital solutions, with a 300MW pipeline target. Analyst consensus is bullish with a $142.75 price target, but high debt levels and negative shareholder equity pose fundamental concerns.
The outlook for IRM is mixed; growth in digital and data center services offers upside, supported by strong analyst buy ratings. However, elevated valuation multiples, significant debt burden, and inconsistent earnings present risks. Investors should weigh the growth potential against financial leverage and margin pressures when considering a position.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Iron Mountain Inc
Iron Mountain Inc is a record management services provider. The firm is organized as a REIT. Most of its revenue comes from its storage business, with the rest coming from value-added services. The firm primarily caters to enterprise clients in developed markets. Its business segments include Global RIM Business
Read more on IRM →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
